Cost fears for Meningitis B lifesaver
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A vaccine against meningitis B that could save thousands of lives has been licensed in the UK and Europe, it was announced yesterday.
The vaccine, called Bexsero, has taken 20 years to develop and is expected to virtually eliminate the toll from the disease which kills and maims hundreds of children every year.
But the cost, which has yet to be announced by its Swiss makers Novartis, could prevent its being made swiftly available through the national vaccination programme.
It has been more difficult to develop than other meningitis vaccines (against different strains) and is likely to cost considerably more.
Campaigners yesterday urged the Government to make it available as soon as possible after a previous jab against pneumococcal meningitis took five years after licensing to be included in the national programme.
The vaccine will be available to buy privately when it is launched by Novartis soon. It has been licensed for use in babies from age two months and provides 73 per cent protection against the disease.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments